Form 4: Tyra Biosciences Director Sells Shares via 10b5-1 Plan

Tyra Biosciences Director Robert J. More sold 246,871 shares of common stock for approximately $20.25 per share through a pre-arranged 10b5-1 trading plan.

Summary

• Robert J. More, a Director of Tyra Biosciences, Inc. (TYRA), reported the sale of 246,871 shares of common stock.
• The transaction occurred on November 21, 2025.
• The shares were sold at a weighted average price of $20.2536 per share, with actual sale prices ranging from $20.25 to $21.24.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. ('APNG II') on June 26, 2025.
• Following the reported transaction, 3,833,425 shares are beneficially owned indirectly by APNG II.
• Robert J. More is a managing director of the general partner of APNG II and shares voting and investment control over the shares held by APNG II, disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director selling a significant number of shares. However, the pre-planned nature of the sale via a 10b5-1 plan mitigates some of the immediate negative implications, preventing a lower score.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction rather than an immediate reaction to new information, which can mitigate negative market perception.

Negatives

• A director's sale of a significant number of shares (246,871) could be perceived negatively by the market, potentially signaling a lack of confidence or a desire to diversify holdings.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report does not provide specific details to analyze its relation to broader industry trends or competitors. It is a routine disclosure of a director's stock activity.

Related Party Transactions

• The shares sold were held directly by Alta Partners NextGen Fund II, L.P. ('APNG II'). The reporting person, Robert J. More, is a managing director of the general partner of APNG II and shares voting and investment control over these shares, making this a related party transaction.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially leading to increased scrutiny of the company's near-term prospects, despite the pre-planned nature of the transaction.

Key Dates

Recommendation

The sale of shares by a director, even if pre-planned via a 10b5-1 plan, can be viewed with caution by the market. However, without additional context on the company's performance, strategic updates, or other insider activity, this single transaction does not provide sufficient grounds for a strong buy or sell recommendation. Investors should hold and monitor further developments and company fundamentals.

Keywords

Tyra Biosciences, TYRA, Form 4, insider trading, stock sale, director, 10b5-1 plan, common stock, Alta Partners NextGen Fund II